Cargando…

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence

Activation of the endothelin A receptor (ET(A)) by endothelin-1 (ET-1) mediates events that regulate mitogenesis, apoptosis, angiogenesis and metastasis in tumours. Specific blockade of ET(A) may have anticancer effects, while retaining beneficial endothelin B receptor (ET(B))-mediated effects such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morris, C D, Rose, A, Curwen, J, Hughes, A M, Wilson, D J, Webb, D J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361809/ https://www.ncbi.nlm.nih.gov/pubmed/15956965 http://dx.doi.org/10.1038/sj.bjc.6602676

Ejemplares similares

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies
por: Tomkinson, Helen, et al.
Publicado: (2011)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
por: Monks, N R, et al.
Publicado: (2001)

4054 Telemedicine Infectious Diseases Consultation in Rural Hospitals: Feasibility, Acceptability, Appropriateness, and Implementation
por: Burnham, Jason P., et al.
Publicado: (2020)

The Higgs as a portal to the hidden sector via an analysis of $H\to Zd_d Z_d \to 4l$ using the ATLAS detector
por: Unwuchola, D A
Publicado: (2015)

Investigating the specificity of endothelin-traps as a potential therapeutic tool for endothelin-1 related disorders
por: Jain, Arjun, et al.
Publicado: (2022)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Endothelin
por: Davenport, Anthony P., et al.
Publicado: (2016)

Production of the Bioactive Compounds Violacein and Indolmycin Is Conditional in a maeA Mutant of Pseudoalteromonas luteoviolacea S4054 Lacking the Malic Enzyme
por: Thøgersen, Mariane S., et al.
Publicado: (2016)

Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.
por: Smith, I., et al.
Publicado: (1996)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).
por: Judson, I., et al.
Publicado: (1998)

A Novel CACNA1A Nonsense Variant [c.4054C>T (p.Arg1352(⁎))] Causing Episodic Ataxia Type 2
por: Lance, Sean, et al.
Publicado: (2018)

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2012)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
por: Magné, N, et al.
Publicado: (2003)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
por: Monks, N R, et al.
Publicado: (2000)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

The accumulation of rare-earth yttrium ions by Penicillium sp. ZD28
por: Wang, Weiying, et al.
Publicado: (2020)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2009)

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
por: Magné, N, et al.
Publicado: (2002)

EDB Fibronectin-Specific SPECT Probe (99m)Tc-HYNIC-ZD2 for Breast Cancer Detection
por: Ye, Xiao-Xuan, et al.
Publicado: (2017)

Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.
por: Freemantle, S. J., et al.
Publicado: (1995)

The HCN Channel Blocker ZD7288 Induces Emesis in the Least Shrew (Cryptotis parva)
por: Zhong, W., et al.
Publicado: (2021)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
por: Groenewegen, G, et al.
Publicado: (2012)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.
por: Aherne, G. W., et al.
Publicado: (1998)

Endothelin 1 levels in relation to clinical presentation and outcome of Henoch Schonlein purpura
por: Fessatou, S, et al.
Publicado: (2008)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007)

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_idjchkd8q4djoff5k8gucvdbae